NVDA 125.53 ▼14.01%GOOGL 265.29 ▼2.70%MSFT 484.52 ▼2.77%AMD 424.39 ▼13.25%INTC 51.28 ▼7.97%TSMC 318.71 ▼9.48%AMZN 246.82 ▼4.10%META 560.84 ▼5.93%AAPL 342.56 ▼1.90%PLTR 143.49 ▼6.63%
Markets at last close

Health

California research funding faces calls for faster treatments

·1 min read

Proposition 38 will invest another $8.4 billion in California medical research, raising questions about how public funding can shorten patients’ wait for treatments. California voters authorized $3 billion in 2004 to create the California Institute for Regenerative Medicine. In 2026, the institute released its first therapy, a treatment for children with a rare immune disorder. Such lengthy development timelines leave patients with fatal diseases waiting for advances they may not live to receive.

AI can analyze large datasets, map genetic mutations and assist drug design. Synthetic organoids mimic human organs and can identify toxic reactions earlier than traditional animal testing. About 9 out of 10 drugs pass animal tests but eventually fail in human trials. Stanford University has accelerated its drug pipelines through human-tissue screening, while Scripps Research Institute has combined research data with AI workflows to reduce processing times from months to days.

Proposed conditions on public funding include accountability milestones, defined timelines, human-focused testing and prompt sharing of findings. The regenerative medicine institute already ties programs to funding milestones and aims to complete each trial within strict two-year timelines. Broader adoption of these practices could help researchers build on discoveries, avoid repeated mistakes and maintain public confidence in research spending.

Originally reported by latimes.comRead the source →
Related coverage